603077 和邦生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.965-2.9390.1656.63322.820
总资产报酬率 ROA (%)0.610-1.8540.1165.27618.117
投入资产回报率 ROIC (%)0.637-1.9690.1275.90220.349

边际利润分析
销售毛利率 (%)24.36511.5207.80123.26142.853
营业利润率 (%)14.798-8.388-0.72317.47234.367
息税前利润/营业总收入 (%)16.983-7.605-0.59317.03834.533
净利润/营业总收入 (%)12.414-9.915-0.82814.49129.222

收益指标分析
经营活动净收益/利润总额(%)85.724-24.834-87.22697.559100.124
价值变动净收益/利润总额(%)-0.8330.7938.6334.8970.487
营业外收支净额/利润总额(%)-0.1464.4355.924-0.379-0.058

偿债能力分析
流动比率 (X)3.8543.1782.6052.6852.603
速动比率 (X)2.5532.1441.7601.4852.047
资产负债率 (%)36.69136.33735.89617.61918.004
带息债务/全部投入资本 (%)32.98832.24231.27010.4039.686
股东权益/带息债务 (%)199.183206.042215.943851.542922.881
股东权益/负债合计 (%)171.791174.400175.007452.708440.575
利息保障倍数 (X)7.694-6.492-3.384-46.256186.635

营运能力分析
应收账款周转天数 (天)46.51035.91337.64035.81117.610
存货周转天数 (天)348.114239.291204.380172.22872.187